Personalized mRNA vaccines have advanced to phase 2 trials for treating pancreatic cancer, utilizing patient-specific genetic codes from tumors to activate an immune response. Born out of COVID-19 research, these vaccines signal the immune system to detect and combat cancer cells, marking a revolutionary stride in cancer immunotherapy. The phase 1 trial at Memorial Sloan Kettering Cancer Center involved 16 patients and revealed promising results. Not only were the vaccines safe, but they also prevented or delayed cancer recurrence in about half the patients. They also boosted the production of T cells, crucial for attacking cancer cells, and this effect lasted up to two years. The ongoing phase 2 trial will assess the efficacy of these vaccines against the current standard treatment. This progress offers a glimmer of hope that cancer can be battled with the power of the immune system.
Full article here: https://medium.com/@lawsuithelpdesk/revolutionary-shift-in-cancer-treatment-personalized-mrna-vaccines-enter-phase-2-trials-for-1fe4c2e24de7
